Cancer Gene Therapy Market Benefits, Opportunities and Future Investments Forecast To 2024
Jun 13, 2019
Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade.
Delaware, Selbyville - June 13, 2019 /MarketersMedia/ —
Cancer Gene Therapy Market size is expected to exceed USD 4.3 billion by 2024; as per a new research report by Global Market Insights, Inc.
Globally, rising cancer prevalence will increase demand for gene therapy as the effective personalized treatment choice. According to WHO, cancer incidence is projected to rise by 50% to reach 15 million by the end of this decade. This alarming increase in number of patients necessitates this as a potential treatment approach addressing the growing global burden of the disease.
Retroviral vector-mediated gene transfer dominated the development by enabling the conversion of single stranded RNA into a double stranded DNA molecule, which steadily integrates into the target cell genome. These vectors are used to permanently modify the host cell nuclear genome and will register a robust growth of over 20%.
Request a sample of this premium report titled at https://www.marketstudyreport.com/request-a-sample/467801/?utm_source=MM-VHS
Growing number of clinical trials and availability of wide range of genes and vectors used in these trials will enable emergence of new treatment modalities to help make cancer a manageable disease. By the end of 2012, the number of clinical trials crossed 1,800 worldwide.
Adenoviral vector remains as the most common oncology application due to its competent nuclear mechanism and low pathogenicity. It is widely used in replacement approaches, suicide and gene-based immunotherapy, and syndicate with chemotherapy and is anticipated to grow at 20% CAGR.
Increased adoption of emerging genomic technologies such as NGS and high density micro array coupled with favorable government initiatives will fuel global cancer gene therapy market size. For instance, CDC supports nationwide screening programs for control of breast, cervical and colorectal cancer among low-income women with little or no health insurance. However, high cost of development lack of reimbursement and regulatory processes will restrain industry growth.
U.S. led the industry owing to increased R&D funding and other government initiatives. Growing number of biotech companies are engaging in R&D and clinical trials of gene therapy products. Increased demand for DNA vaccines and increasing interest of venture capitalists to invest in commercialization of gene therapies will trigger industry expansion.
China cancer gene therapy market size attributed to over 35% APAC revenue in 2015. With the launch of Gendicine and increasing healthcare expenditure and robust R&D facilities will enable industry growth.
Key insights from the report include:
U.S. cancer gene therapy market share accounted for over 95% regional revenue in 2015, with market size of USD 235 million and a forecast to grow at 20.9% CAGR.
Request a discount on standard prices of this premium report titled at https://www.marketstudyreport.com/check-for-discount/467801/?utm_source=MM-VHS
UK was over USD 92.0 million in 2015, and will grow at 20.8% CAGR owing to increasing incidence of cancer and adoption of advanced treatment methods.
China market size was valued at USD 99.6 million in 2015 and growth expectations of 21% CAGR over the forecast years.
Key players include SiBiono, Altor Bioscience Corporation, Shanghai Sunway Biotech company limited, Amgen, BioCancell, OncoGeneX, Aduro Biotech, GlobeImmune, Inc., New Link Genetics., ZioPharm Oncology, MolMed, GENELUX, Gradalis, MultiVir.
The industry is highly fragmented and is dominated by several small biotech firms collectively accounting for over 80% of cancer gene therapy market pipeline. Major growth strategies adopted by these small firms include, technology transfer, licensing and commercialization deals, strategic collaborations and mergers and acquisitions to retain their industry position.
Report Content
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.1.1. Initial data exploration
1.1.2. Statistical modeling and forecast
1.1.3. Industry insights and validation
1.1.4. Research scope & assumptions
1.2. Data Sources
Chapter 2. Executive Summary
2.1. Cancer genetics industry 360 degree synopsis, 2012 - 2024
2.1.1. Business trends
2.1.2. Regional trends
2.1.3. Application trends
Chapter 3. Cancer Gene Therapy Industry Insights
3.1. Industry segmentation
3.2. IIndustry Size and forecast, 2012 - 2024
3.3. Industry Impact forces
3.3.1. Growth drivers
3.3.1.1. Technological advancements
3.3.1.2. Increased adoption of nanotechnology
3.3.1.3. Favorable government regulations
3.3.2. Industry pitfalls & challenges
3.3.2.1. High cost of cancer genetherapy
3.4. Growth potential analysis
3.5. Porter's analysis
3.6. Key opportunities prioritized, 2015
3.7. PESTEL analysis
3.8. Regulatory Landscape
3.8.1. U.S.
3.8.2. EU
3.8.3. China
3.9. Scientific and Ethical issues in Gene Therapy
3.10. Competitive landscape, 2015
3.11. Pipeline Analysis by cancer type
3.11.1. Head and Neck Cancer Pipeline Analysis
3.11.2. Breast Cancer Pipeline Analysis
3.11.3. Gastro Intestinal Cancer Pipeline Analysis
3.11.4. Gentiourinary Cancer Pipeline Analysis
3.11.5. Gynecological Cancer Pipeline Analysis
3.11.6. Haemotological Cancer Pipeline Analysis
3.11.7. Neurologic Cancer Pipeline Analysis
3.11.8. Respiratory Cancer Pipeline Analysis
3.11.9. Skin Cancer Pipeline Analysis
Chapter 4. Cancer Gene Therapy Insights
4.1. Cancer gene therapy market share by therapy, 2015 & 2024
4.2. Gene Induced Immunotherapy
4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.2. Delivery of cytokine gene
4.2.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.2.3. Delivery of tumor antigen gene
4.2.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3. Oncolytic Virotherapy
4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.2. Adenoviruses
4.3.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.3. Lentiviruses
4.3.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.4. Retrovirus
4.3.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.5. Adeno Associated Virus
4.3.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.6. Herpes Simplex Virus
4.3.6.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.7. Alphavirus
4.3.7.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.8. Vaccinia Virus
4.3.8.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.9. Simian Virus
4.3.9.1. Market estimates and forecast, 2012-2024 (USD Million)
4.3.10. Others
4.3.10.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4. Gene transfer/ Gene replacement
4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.2. Naked/Plasmid Vectors
4.4.2.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.3. Electroporation
4.4.3.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.4. Sonoportion
4.4.4.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.5. Magnetofection
4.4.5.1. Market estimates and forecast, 2012-2024 (USD Million)
4.4.6. Gene Gun
4.4.6.1. Market estimates and forecast, 2012-2024 (USD Million)
Complete report titled at https://www.marketstudyreport.com/reports/cancer-gene-therapy-market
About Us:
Marketstudyreport.com allows you to manage and control all corporate research purchases to consolidate billing and vendor management. You can eliminate duplicate purchases and customize your content and license management.
Contact Info:
Name: Arun Hegde
Email: Send Email
Organization: Market Study Report
Address: 4 North Main Street, Selbyville, Delaware 19975 USA
Phone: 1-302-273-0910
Website: https://www.marketstudyreport.com/
Source: MarketersMedia
Release ID: 524003
More News
Sara Duterte impeachment trial Day 41: What to expect
The defense panel will present on Tuesday its second witness in the impeachment trial of Vice President Sara Duterte to testify on matters concerning the tax declarations and tax maps of a property in the Island Garden City of Samal.
Lotto draw results on Monday, November 9
MANILA, Philippines—No ticket holder won the Grand Lotto 6/55 and Mega Lotto 6/45 jackpot on Monday, November 9, 2026, according to the Philippine Charity Sweepstakes Office. Grand Lotto 6/55 draw result: 53-44-36-18-20-28. Jackpot prize: ₱349.05 million Mega Lotto 6/45 draw result: 29-27-12-11-43-05. Jackpot prize: ₱15 million. Minor games The PCSO also reported the following results
Dy: House will soon launch transparency platform on its website
MANILA, Philippines — The House of Representatives will soon launch a transparency platform on its website that will allow Filipinos to scrutinize government-funded projects, including their locations, funding allocations, and implementation status, Speaker Faustino “Bojie” G. Dy III announced on Monday. The project is part of continuing reforms to strengthen transparency and accountability in public
Butuan drug suspect busted, over P700,000 shabu seized
A 30-year-old suspect, alias “Cyclone,” was arrested in a drug buy-bust operation in Barangay Ong Yiu, Butuan City on Sunday, Nov. 8, 2026.(Photo courtesy of Police Regional Office 13) SAN FRANCISCO, Agusan del Sur – Anti-narcotics operatives seized over P700,000 worth of suspected shabu from an alleged street-level drug pusher arrested in an entrapment operation
Baguio City Mayor Magalong urges responsible use of AI in schools
BAGUIO CITY—Mayor Benjamin Magalong has urged education leaders to promote the ethical and responsible use of artificial intelligence (AI) in schools, emphasizing that the technology should support learning rather than make students dependent on it. In a statement Sunday, Nov. 8, Magalong stressed the need for proper and controlled use of AI in education during
Luistro presses Mans Carpio to testify on assets shared with VP
MANILA, Philippines — The House prosecution is wondering who will explain the financial records and disputed assets of Vice President Sara Duterte and her husband, lawyer Manases “Mans” Carpio, considering that the latter is not in the initial witness list of the defense. Rep. Gerville Luisto, the lead prosecutor, pointed this out on Sunday in
Rodrigo Duterte defense team wants ICC prosecution witnesses vs Bato dela Rosa removed
The defense team of former President Rodrigo Duterte has pushed back at International Criminal Court prosecutors over their bid to include two witness testimonies whose accounts they allege to be based on “rumors, hearsay, and information obtained through media.”
Closed fishing season may trigger price hike, supply issues – Pamalakaya
MANILA, Philippines—The upcoming closed fishing season in major fishing grounds across the country could trigger an artificial shortage of fish and drive up market prices, the fishers’ group Pambansang Lakas ng Kilusang Mamamalakaya ng Pilipinas (Pamalakaya) warned. In a statement, Pamalakaya said the annual three-month fishing ban, scheduled across several fishing grounds between November and
Pope names Mati bishop as new head of Davao archdiocese
MANILA, Philippines — Mati Bishop Abel Apigo was appointed by Pope Leo XIV as the new archbishop of Davao, succeeding Archbishop Romulo Valles, who already reached the mandatory retirement age for bishops, according to CBCP News. Apigo was appointed as the second bishop of Mati by Pope Francis in 2018. He completed his philosophical and
Doubled night shift differential for private sector workers pushed
MANILA, Philippines — A bill seeking to double the minimum night shift differential for private-sector workers from the current 10 percent to 20 percent of their regular hourly wage has been filed by Sen. Loren Legarda. According to Legarda, the proposed increase would help recognize the sacrifices and health risks faced by workers whose schedules
Pagadian City hosts 2026 MindaCon, more tech investments seen
PAGADIAN CITY, Zamboanga del Sur – The National ICT (Information and Communications Technology) Confederation of the Philippines (NICP) has reaffirmed its commitment to driving digital transformation in the countryside. During Monday’s opening of 11th Mindanao ICT Conference (MindaCon) 2026 from Nov. 9 to 11, NICP president Jessraf Palmares lauded the city government’s thrust toward digital
Caraga poverty rate drops to 7.8% in 2025
SAN FRANCISCO, Agusan del Sur — Poverty incidence among families in Caraga (Region 13) dropped to 7.8 percent in 2025, according to preliminary results of the 2025 Family Income and Expenditure Survey (FIES) released on Monday by the Philippine Statistics Authority (PSA). The official report, issued by the PSA Regional Statistical Services Office-13 (Caraga), showed
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.